Core Viewpoint - Fujian Haixi New Drug Creation Co., Ltd. (referred to as "Haixi New Drug") was listed on the Hong Kong Stock Exchange, with a closing price of 104.20 HKD on the first day, reflecting a 20.60% increase, but it dropped to 101.5 HKD the following day, a decrease of 2.59% [1]. Summary by Sections Share Issuance and Capital Structure - The total number of shares issued under the global offering was 11,500,000 H-shares, with 1,150,000 H-shares available for public offering and 10,350,000 H-shares for international offering [2]. - At the time of listing, the total number of shares issued was 78,707,270 [2]. Pricing and Proceeds - The final offering price was set at 86.40 HKD, resulting in total proceeds of 993.60 million HKD. After deducting estimated listing expenses of 53.47 million HKD, the net proceeds amounted to 940.13 million HKD [4][5]. Use of Proceeds - Approximately 52.0% of the net proceeds is expected to be used for ongoing investment in research and development to advance the drug pipeline and enrich the product portfolio. About 23.0% is anticipated for enhancing R&D capabilities and seeking collaboration opportunities. Additionally, 8.0% is planned for strengthening commercialization capabilities and expanding market influence, while 7.0% is allocated for improving and optimizing R&D and production systems, and 10.0% for working capital and other general corporate purposes [6]. Company Overview - Haixi New Drug is a commercial-stage pharmaceutical company that integrates R&D, production, and sales capabilities, with a pipeline of innovative drugs under development [6]. Financial Performance - The company's revenues for the years 2022, 2023, 2024, and the first five months of 2025 were 212.5 million, 316.6 million, 466.7 million, and 249.2 million RMB, respectively. The net profits for the same periods were 69.0 million, 117.5 million, 136.1 million, and 90.2 million RMB [7][8]. - The net cash flow from operating activities for the same periods was 85.3 million, 147.1 million, 163.9 million, and 80.1 million RMB [9]. Research and Development Pipeline - As of July 2025, Haixi New Drug has only four innovative drugs in the pipeline, all in early clinical stages. These include a multi-mechanism immune modulator C019199 for treating osteosarcoma and other malignancies, an oral small molecule drug HXP056 recently approved for clinical trials targeting wet age-related macular degeneration, and two other drugs for tumors and respiratory diseases still in preclinical research [10].
海西新药上市次日跌2.6% 募9亿港元创新药管线“断档”